Linden Lake Venture Capital
Linden Lake Ventures, founded in 2019 and based in Bethesda, Maryland, is a venture capital firm that specializes in early-stage biotechnology investments. The firm focuses on developing transformative molecular medicines for patients in need, targeting sectors such as oncology, immunology, hepatology, cardiovascular, respiratory, neurology, orphan diseases, small molecules, biologics, and gene and cell therapy. Linden Lake Ventures employs a hands-on investment approach, primarily concentrating on pre-clinical and phase I technologies to foster innovation in the biotechnology landscape.
CrossBridge Bio
Seed Round in 2024
CrossBridge Bio is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes proprietary linker technology and enzymatic conjugation methods to create stable and targeted ADC therapeutics. This approach aims to improve the efficacy and safety profiles of cancer therapies, offering potential advancements in the treatment landscape. By leveraging its unique dual linker payload technology, CrossBridge Bio seeks to revolutionize how cancer is treated, providing new options for patients and healthcare providers.
Vesigen Therapeutics
Series A in 2020
Vesigen Therapeutics, established in 2020 and based in Cambridge, Massachusetts, specializes in developing innovative therapeutic products. The company's core technology, ARMMs (ARRDC1 Mediated Microvesicles), facilitates the delivery of various payloads such as RNAs, proteins, and gene-editing complexes directly into the cytoplasm of target cells. This approach overcomes intracellular delivery barriers, expanding the scope of treatable conditions and enabling the development of novel therapies for unmet medical needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.